摘要
目的:通过抗凋亡蛋白Bcl-2的检测,观察其在非霍奇金淋巴瘤（NHL）中的表达及临床意义。方法:用免疫组织化学染色的方法,对34例NHL外检石蜡包埋组织切片进行Bcl-2蛋白的检测。结果:（1）低度恶性NHL中Bcl-2表达高于高度恶性组（P<0.005）;（2）B细胞性NHL中Bcl-2的表达高于T细胞性NHL（P<0.025）;（3）首次化疗缓解组中的Bcl-2表达低于未缓解组（P<0.01）;（4）高Bcl-2表达组的生存期与低表达组之间无差异。结论:抗凋亡蛋白Bcl-2的表达与NHL恶性程度及化疗缓解率相关,可能成为NHL预后的判断指标。
Objective: To evaluate the expression of apoptosisa-antagonizing Bcl-2 and its clinical significance in non-Hodgkin's lymphoma (NHL) . Methods: The Bcl-2 protein was measured by immunohistochemistry on paraffin-embedded specimens in 34 cases of NHL. Results: (1) The expression of Bcl-2 in the low grade NHL was significantly higher than that in the high grade NHL(P<0.005) . (2) The expression of Bcl-2 in B cell NHL was higher than that in T cell NHL (P<0.025). (3) The expression of Bcl-2 in remission group was lower than that in the non ?remission group during the first chemotherapeutics. (4) There was no significant difference about survival time between high and low Bcl-2 expression groups. Conclusion: Bcl-2 was positively related with the malignant grade and remission of chemotherapeutics. Maybe it was a marker for the prognosis.
出处
《临床肿瘤学杂志》
CAS
2001年第1期18-20,共3页
Chinese Clinical Oncology
